FDA应用监管科学部新方法学进展
本文综述了FDA应用监管科学部(DARS)在新方法学(NAMs)开发、验证与监管应用方面的近期进展,涵盖计算机模拟与体外NAMs。案例表明NAMs可减少对动物研究的依赖并改善临床转化,部分方法已用于监管审评。
要点
- 计算机模拟NAMs包括QSP建模、Q(SAR建模和多组学方法。
- 体外NAMs包括hiPSC衍生神经网络、MPS和标准化心脏离子通道检测。
- NAMs从探索性工具发展为可支持监管审评的方法。
核心结论
- 将计算机模拟与体外NAMs整合入监管决策框架,是迈向更高效、更人源相关药物开发与安全性评估的关键步骤。
研究设计与样本
- 本文为来自FDA应用监管科学部(DARS)的迷你综述,介绍NAMs的开发、验证与监管应用进展。
主要发现
- 计算机模拟NAMs包括用于阿片类药物过量场景的定量系统药理学(QSP)建模、用于毒性预测和药物相互作用评估的(定量)构效关系((Q)SAR)建模以及用于药效生物标志物发现的多组学方法。
- 体外NAMs包括用于阿片药理学评估的人诱导多能干细胞(hiPSC)衍生神经网络、用于肺部药物渗透的微生理系统(MPS)、用于肠道转运的胃肠道模型以及用于致心律失常风险预测的标准化心脏离子通道和hiPSC-CM MEA检测。
- 所述NAMs从探索性研究工具到已积极为监管提交审评提供信息的方法不等。
临床怎么用
- 临床药学智能体医生可关注NAMs在药物相互作用评估、毒性预测和致心律失常风险预测等方面的监管应用进展,以理解监管决策依据的演变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
New Approach Methodologies (NAMs) represent a paradigm shift in drug development and regulatory science, offering human-relevant alternatives to traditional preclinical models. This mini-review highlights recent advances in NAM development, validation, and regulatory application from FDA's Division of Applied Regulatory Science (DARS). We describe in silico NAMs including quantitative systems pharmacology (QSP) modeling for opioid overdose scenarios, (quantitative) structure-activity relationship ((Q)SAR) modeling for toxicity prediction and drug-drug interaction assessment, and multi-omics approaches for pharmacodynamic biomarker discovery. Additionally, we present in vitro NAMs including human-induced pluripotent stem cell (hiPSC)-derived neural networks for opioid pharmacology assessment, microphysiological systems (MPS) for pulmonary drug permeability, gastrointestinal models for intestinal transport, and standardized cardiac ion channel and hiPSC-CM MEA assays for proarrhythmia risk prediction. These case studies demonstrate how NAMs can reduce reliance on animal studies while improving translation to clinical outcomes. The NAMs described here range from exploratory research tools to approaches actively informing regulatory submissions review. The integration of in silico and in vitro NAMs into regulatory decision-making frameworks represents a critical step toward more efficient, human-relevant drug development and safety assessments.
引用
- Blinova K, Chiu K, Chaturbedi A, et al. Advances in New Approach Methodologies at FDA's Division of Applied Regulatory Science. Clin Pharmacol Ther. 2026. PMID: 42687608. doi:10.1002/cpt.70472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。